SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO) being held February 12- 15 in Vienna, Austria.
Details for the ECCO presentations are as follows:
Session Type: Poster Exhibition Section Title: Basic Science Session Date and Time: Friday, February 14, 2020; 12:30- 1:30 p.m. CET Poster Number: P034 Poster Title: GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor, Induces HIF-1α Target Genes and is Efficacious in Mouse Colitis Presenter Name: Kristen Talyor Meadows, Ph.D. Location: Hall C – Reed Messe Vienna Congress Center
Session Type: Poster Exhibition Section Title: Clinical: Therapy and Observation Session Date and Time: Friday, February 14, 2020; 12:30- 1:30 p.m. CET Poster Number: P540 Poster Title: GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First In-Human Multiple Dose Study in Healthy Subjects With Gut Biopsies Presenter Name: Barrett Levesque, M.D. Location: Hall C – Reed Messe Vienna Congress Center
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005151/en/
For Investors: Argot Partners Tel 212.600.1902 gossamerbio@argotpartners.com
For Media: Argot Partners David Rosen Tel 212.600.1902 david.rosen@argotpartners.com
Source: Gossamer Bio, Inc.